SCHEMBL884356

SCHEMBL884356

CS(=O)(=O)N(c1ccccn1)c1ccccc1CC(c1cccnc1)c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 15/20 0.48
KCNH2 Q12809 6/20 0.46
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CFTR P13569 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
GOPC Q9HD26 1/20 0.35
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
ITGB7 P26010 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL885100 0.75 KCNA5 (0.73) KCNA5KCNH2LMNASMN1; SMN2L3MBTL1
SCHEMBL884789 0.70 KCNA5 (0.45) KCNA5KCNH2
SCHEMBL885143 0.70 KCNA5 (0.53) KCNA5KCNH2ALDH1A1SMN1; SMN2CFTR
SCHEMBL10094161 0.69 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL2062650 0.69 KCNA5 (0.48) KCNA5KCNH2SLC6A3
SCHEMBL885471 0.69 KCNA5 (0.66) KCNA5KCNH2LMNASMN1; SMN2L3MBTL1
SCHEMBL884725 0.68 KCNA5 (0.61) KCNA5KCNH2
SCHEMBL884728 0.68 KCNA5 (0.74) KCNA5KCNH2SMN1; SMN2CFTRSLC6A2
SCHEMBL884727 0.67 KCNA5 (0.59) KCNA5KCNH2LMNASMN1; SMN2L3MBTL1
SCHEMBL2063083 0.67 KCNA5 (0.64) KCNA5KCNH2LMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP disclosed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885ALDH1A1 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.